277 related articles for article (PubMed ID: 10912316)
1. Ramipril.
Smith WH; Ball SG
Int J Clin Pract; 2000 May; 54(4):255-60. PubMed ID: 10912316
[TBL] [Abstract][Full Text] [Related]
2. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
Rapezzi C; Ciliberti P; Graziosi M; Riva L
Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
[TBL] [Abstract][Full Text] [Related]
3. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
Gerstein HC
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
[TBL] [Abstract][Full Text] [Related]
4. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.
Can J Cardiol; 1996 Feb; 12(2):127-37. PubMed ID: 8605634
[TBL] [Abstract][Full Text] [Related]
5. Diabetes and the HOPE study: implications for macrovascular and microvascular disease.
Gerstein HC
Int J Clin Pract Suppl; 2001 Jan; (117):8-12. PubMed ID: 11715357
[TBL] [Abstract][Full Text] [Related]
6. Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*.
Schrader J; Lüders S; Kulschewski A; Hammersen F; Züchner C; Venneklaas U; Schrandt G; Schnieders M; Rangoonwala B; Berger J; Dominiak P; Zidek W;
J Hypertens; 2006 Mar; 24(3):541-8. PubMed ID: 16467658
[TBL] [Abstract][Full Text] [Related]
7. The HOPE Study (Heart Outcomes Prevention Evaluation).
Sleight P
J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.
Bosch J; Lonn E; Pogue J; Arnold JM; Dagenais GR; Yusuf S;
Circulation; 2005 Aug; 112(9):1339-46. PubMed ID: 16129815
[TBL] [Abstract][Full Text] [Related]
9. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.
McQueen MJ; Lonn E; Gerstein HC; Bosch J; Yusuf S
Scand J Clin Lab Invest Suppl; 2005; 240():143-56. PubMed ID: 16112972
[TBL] [Abstract][Full Text] [Related]
10. ACE inhibition in cardiovascular disease.
Francis GS
N Engl J Med; 2000 Jan; 342(3):201-2. PubMed ID: 10639547
[No Abstract] [Full Text] [Related]
11. Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?
Boos CJ
Med Sci Monit; 2004 Dec; 10(12):SR23-8. PubMed ID: 15567997
[TBL] [Abstract][Full Text] [Related]
12. Ramipril in the treatment of vascular diseases.
Rokoss MJ; Teo KK
Expert Opin Pharmacother; 2005 Sep; 6(11):1911-9. PubMed ID: 16144510
[TBL] [Abstract][Full Text] [Related]
13. Current indications for ACE inhibitors and HOPE for the future.
Burch S; Ou N
Am J Manag Care; 2002 May; 8(5):478-90; quiz 491-3. PubMed ID: 12019599
[TBL] [Abstract][Full Text] [Related]
14. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.
Dinicolantonio JJ; Lavie CJ; O'Keefe JH
Postgrad Med; 2013 Jul; 125(4):154-68. PubMed ID: 23933903
[TBL] [Abstract][Full Text] [Related]
15. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
Lüders S; Schrader J; Berger J; Unger T; Zidek W; Böhm M; Middeke M; Motz W; Lübcke C; Gansz A; Brokamp L; Schmieder RE; Trenkwalder P; Haller H; Dominiak P;
J Hypertens; 2008 Jul; 26(7):1487-96. PubMed ID: 18551027
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin receptor blockers: novel role in high-risk patients.
Javed U; Deedwania PC
Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
[TBL] [Abstract][Full Text] [Related]
17. Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding?
Mancini GB; Stewart DJ
Can J Cardiol; 2001 May; 17 Suppl A():15A-7A. PubMed ID: 11381289
[TBL] [Abstract][Full Text] [Related]
18. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
Lancet; 2000 Jan; 355(9200):253-9. PubMed ID: 10675071
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
